Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 5/20 | 0.46 |
| ▸ | FNTB | P49356 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115234 | 1.00 | KDM4E (0.52) | KDM4EATMFNTAFNTBPOLB | |
| SCHEMBL25243560 | 0.92 | KMT2A (0.59) | KDM4EATMFNTAFNTBKMT2A | |
| SCHEMBL25235501 | 0.92 | KMT2A (0.59) | KDM4EATMFNTAFNTBKMT2A | |
| SCHEMBL2129883 | 0.88 | KDM4E (0.41) | KDM4EATMFNTAFNTBPOLB | |
| SCHEMBL2127672 | 0.84 | FNTA (0.45) | KDM4EATMFNTAFNTBPOLB | |
| SCHEMBL5506863 | 0.82 | FNTA (0.54) | KDM4EATMFNTAFNTBPOLB | |
| SCHEMBL584815 | 0.79 | FNTA (0.42) | KDM4EATMFNTAFNTBPOLB | |
| SCHEMBL907663 | 0.79 | ALOX15 (0.52) | KDM4EATMFNTAFNTBALDH1A1 | |
| SCHEMBL1797117 | 0.79 | ALOX15 (0.52) | KDM4EATMFNTAFNTBALDH1A1 | |
| SCHEMBL21727766 | 0.79 | HPGD (0.38) | KDM4EATMFNTAFNTBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187978-B2 | Use of (3-acetoxy-2,2-dimethyl-propyl) acetate in combination with (3-hydroxy-2,2-dimethyl-propyl) acetate as an aroma chemical | BASF SE (DE) | 2025-01-07 | — | — | US | claimed |
| US-10876081-B2 | Method for the production of scent capsules with improved surfactant stability | SYMRISE AG (DE) | 2020-12-29 | — | — | US | claimed |
| EP-3423028-B1 | METHOD FOR THE PRODUCTION OF ENCAPSULATED FRAGRANCE WITH IMPROVED STABILITY AGAINST DETERGENTS | SYMRISE AG (DE) | 2020-04-08 | — | — | EP | claimed |
| WO-2020015880-A1 | BI-PHASE DEODORIZING COSMETIC COMPOSITION | BEIERSDORF AG (DE) | 2020-01-23 | — | — | WO | claimed |
| EP-3423028-A1 | METHOD FOR THE PRODUCTION OF SCENT CAPSULES WITH IMPROVED SURFACTANT STABLITY | Symrise AG (DE) | 2019-01-09 | — | — | EP | claimed |
| EP-1448757-B2 | PRO-PERFUME COMPOSITIONS USED IN CLEANING OR FABRIC TREATMENT PRODUCTS | PROCTER & GAMBLE (US) | 2015-04-08 | — | — | EP | claimed |
| EP-2020225-B1 | Fragrance composition | KAO CORP (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-1448757-B1 | PRO-PERFUME COMPOSITIONS USED IN CLEANING OR FABRIC TREATMENT PRODUCTS | PROCTER & GAMBLE (US) | 2012-05-30 | — | — | EP | claimed |
| WO-2011147455-A1 | FLAVORING SUBSTANCE-INCLUDED COMPOUNDS | SYMRISE AG (DE) | 2011-12-01 | — | — | WO | claimed |
| US-8034761-B2 | Jasmone, peach fragrance | SYMRISE AG (DE) | 2011-10-11 | — | — | US | claimed |
| EP-1848702-A2 | PRO-FRAGRANCE AND PRO-FLAVORANT COMPOSITIONS | Flexitral, Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| US-20060205632-A1 | Pro-fragrance and pro-flavorant compositions | FLEXITRAL, INC. | 2006-09-14 | — | — | US | claimed |
| WO-2006085048-A2 | PRO-FRAGRANCE AND PRO-FLAVORANT COMPOSITIONS | FLEXITRAL, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-6858575-B2 | Pro-perfume compositions and substrate-treating products and methods using them | PROCTER & GAMBLE COMPANY (US) | 2005-02-22 | — | — | US | claimed |
| EP-1448757-A1 | PRO-PERFUME COMPOSITIONS USED IN CLEANING OR FABRIC TREATMENT PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030171250-A1 | Pro-perfume compositions and substrate-treating products and methods using them | THE PROCTER & GAMBLE COMPANY | 2003-09-11 | — | — | US | claimed |
| WO-2003046118-A1 | PRO-PERFUME COMPOSITIONS USED IN CLEANING OR FABRIC TREATMENT PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1314777-A1 | Pro-perfume compositions used in cleaning or fabric treatment products | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-28 | — | — | EP | claimed |
| US-12630783-B2 | Muguet type fragrance compounds | SYMRISE AG (DE) | 2026-05-19 | — | — | US | disclosed |
| EP-1067126-A2 | Tetracyclic acetals | HAARMANN & REIMER GMBH (DE) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630783-B2 | Muguet type fragrance compounds | MGAT1, RFT1, CPT1A | KDM4E 590/4885ATM 4367/4885FNTA 321/4885 |
| US-10876081-B2 | Method for the production of scent capsules with improved surfactant stability | SMOX, LIPA, SGMS2 | KDM4E 2386/4885ATM 2538/4885FNTA 261/4885 |
| US-20030171250-A1 | Pro-perfume compositions and substrate-treating products and methods using them | FASN, ALOX5, PAM | KDM4E 4323/4885ATM 1225/4885FNTA 3059/4885 |
| US-20060205632-A1 | Pro-fragrance and pro-flavorant compositions | TAS2R10, TAS2R9, OR10J3 | KDM4E 2618/4885ATM 3630/4885FNTA 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.